Weekly, seasonal, and chronotype-dependent variation of dim-light melatonin onset.
Comparative StudyHuman subjects
Names both DIM and Melatonin in its title.
Supplement × Supplement·Evidence index
PubMed indexes 8 records that name DIM and Melatonin together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.
Every statement below is attributed to a named, dated, linked source.
This page lists published research relevant to DIM and Melatonin. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.
Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.
Names both DIM and Melatonin in its title.
“For many years, the DLMO was determined mainly with the 'gold standard' GCMS technique for measuring melatonin in human plasma. However, new and improved RIAs now provide the requisite sensitivity and accuracy (specificity) for detecting the time that low daytime levels begin to increase in the evening: the lower the operational threshold for the DLMO, the more reliable it is as a phase marker.”
Names both DIM and Melatonin in its title.
Names both DIM and Melatonin in its title.
“When able to be calculated, DLMOff showed strong associations with sleep timing, suggesting it could be a reliable marker of circadian phase. However, high variability and fluctuating morning melatonin patterns make DLMOff difficult to determine in many preschool-aged children.”
Names both DIM and Melatonin in its title.
“These findings suggest that pDLMO-based phase angles, which can be easily measured in naturalistic settings, can help identify circadian-sleep misalignment in clinical practice. Expanded use of pDLMO may therefore help guide personalized sleep and chronobiological interventions.”
Names both DIM and Melatonin in its title.
Names both DIM and Melatonin in its title.
“Our findings suggested that melatonin may regulate microglial polarization through MT2/NF-kB-NLRP3 pathway and improves dim blue light -induced hippocampal neuroinflammation in mice.”
Names both DIM and Melatonin in its title.
“An evaluation of 14 saliva DLMO studies of clinically diagnosed patients living with delayed sleep-wake phase disorder (mean ages 20 to 31 years) revealed mean saliva DLMO within the reference range albeit at the late extreme. Peak plasma melatonin levels from 179 studies of healthy participants revealed a high degree of variability within studies and age groups, but only a small decline between the 20 and 50 years and lowest levels after 70 years.”
Names both DIM and Melatonin in its title.
Search-based evidence indexes have real limits, and it is worth being explicit about them:
NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers DIM, Melatonin, and several hundred other substances.
The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.